Selexipag

UPTRAVI, UPTRAVI Titration Pack

Prostacyclin Receptor Agonist

NADAC/unit N/A

No Shortage Tier 1: 109.4% PA Req: 536.2% 1 Manufacturers 6 ANDAs

UPTRAVI is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for ....

Covered Lives

Generic Manufacturers

ACTELION PHARMACEUTICALS US INCALEMBIC PHARMACEUTICALS LTD

Explore in the Ecosystem

rxsaver.aiCompare prices for Selexipag drfinder.aiFind doctors who prescribe Selexipag rxbenefits.aiEmployer cost impact analysis clinicalrx.aiClinical profile: Selexipag

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.